VYGR - ボイジャ―・セラピュ―ティクス (Voyager Therapeutics Inc.)

VYGRのニュース

   Voyager Therapeutics Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2020/11/04 19:19:00 Stock Market Daily
Voyager Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease  2020/09/11 15:32:00 PR Newswire
SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment…
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Voyager Therapeutics : Down 15% on End of AbbVie Collaborations | MarketScreener  2020/08/03 21:06:00 MarketScreener
By Josh Beckerman Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody… | August 3, 2020
   Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences  2020/08/03 20:30:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on…
   Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease  2020/09/11 15:32:00 PR Newswire
SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment…
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Voyager Therapeutics : Down 15% on End of AbbVie Collaborations | MarketScreener  2020/08/03 21:06:00 MarketScreener
By Josh Beckerman Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody… | August 3, 2020
   Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences  2020/08/03 20:30:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on…
   AbbVie bails on neurodegenerative disease collaboration with Voyager Therapeutics (NASDAQ:VYGR)  2020/08/03 20:23:41 Seeking Alpha
Voyager Therapeutics (NASDAQ:VYGR) announces the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie (NYSE:ABBV) ther
   Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease  2020/09/11 15:32:00 PR Newswire
SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment…
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Voyager Therapeutics : Down 15% on End of AbbVie Collaborations | MarketScreener  2020/08/03 21:06:00 MarketScreener
By Josh Beckerman Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody… | August 3, 2020
   Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences  2020/08/03 20:30:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on…
   AbbVie bails on neurodegenerative disease collaboration with Voyager Therapeutics (NASDAQ:VYGR)  2020/08/03 20:23:41 Seeking Alpha
Voyager Therapeutics (NASDAQ:VYGR) announces the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie (NYSE:ABBV) ther

calendar